British pharmaceutical giant AstraZeneca said an interim analysis of clinical trials showed its coronavirus vaccine has an average efficacy of 70% in protecting against the virus.
One dosing regimen shows a vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least a month apart. The second dosing regimen shows 62% efficacy when given two full doses at least a month apart.
Combined analysis has an average efficacy of 70%.
Pascal Soriot, CEO of AstraZeneca, said the development marked an “important milestone” in the fight against the global health crisis.
“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Soriot said.
AstraZeneca said it would immediately prepare the regulatory submission of the data to health authorities around the world that have a framework in place for conditional or early approval.
In a statement said by Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial, “These findings show that we have an effective vaccine that will save many lives.”
“Excitingly, we’ve found that one of our dosing regimens maybe around 90% effective and if this dosing regime is used, more people could be vaccinated with a planned vaccine supply,” he added.